S&P 500   4,569.78 (-0.54%)
DOW   36,204.44 (-0.11%)
QQQ   386.32 (-0.93%)
AAPL   189.43 (-0.95%)
MSFT   369.14 (-1.43%)
META   320.02 (-1.48%)
GOOGL   129.27 (-1.96%)
AMZN   144.84 (-1.49%)
TSLA   235.58 (-1.36%)
NVDA   455.10 (-2.68%)
NIO   7.32 (+2.38%)
BABA   73.03 (-1.30%)
AMD   118.57 (-2.32%)
T   16.67 (-0.60%)
F   10.70 (+1.13%)
MU   74.29 (-2.16%)
CGC   0.76 (+22.72%)
GE   121.50 (-0.82%)
DIS   92.01 (-0.62%)
AMC   7.50 (+9.18%)
PFE   29.25 (+1.18%)
PYPL   59.85 (+0.34%)
XOM   102.43 (-0.54%)
S&P 500   4,569.78 (-0.54%)
DOW   36,204.44 (-0.11%)
QQQ   386.32 (-0.93%)
AAPL   189.43 (-0.95%)
MSFT   369.14 (-1.43%)
META   320.02 (-1.48%)
GOOGL   129.27 (-1.96%)
AMZN   144.84 (-1.49%)
TSLA   235.58 (-1.36%)
NVDA   455.10 (-2.68%)
NIO   7.32 (+2.38%)
BABA   73.03 (-1.30%)
AMD   118.57 (-2.32%)
T   16.67 (-0.60%)
F   10.70 (+1.13%)
MU   74.29 (-2.16%)
CGC   0.76 (+22.72%)
GE   121.50 (-0.82%)
DIS   92.01 (-0.62%)
AMC   7.50 (+9.18%)
PFE   29.25 (+1.18%)
PYPL   59.85 (+0.34%)
XOM   102.43 (-0.54%)
S&P 500   4,569.78 (-0.54%)
DOW   36,204.44 (-0.11%)
QQQ   386.32 (-0.93%)
AAPL   189.43 (-0.95%)
MSFT   369.14 (-1.43%)
META   320.02 (-1.48%)
GOOGL   129.27 (-1.96%)
AMZN   144.84 (-1.49%)
TSLA   235.58 (-1.36%)
NVDA   455.10 (-2.68%)
NIO   7.32 (+2.38%)
BABA   73.03 (-1.30%)
AMD   118.57 (-2.32%)
T   16.67 (-0.60%)
F   10.70 (+1.13%)
MU   74.29 (-2.16%)
CGC   0.76 (+22.72%)
GE   121.50 (-0.82%)
DIS   92.01 (-0.62%)
AMC   7.50 (+9.18%)
PFE   29.25 (+1.18%)
PYPL   59.85 (+0.34%)
XOM   102.43 (-0.54%)
S&P 500   4,569.78 (-0.54%)
DOW   36,204.44 (-0.11%)
QQQ   386.32 (-0.93%)
AAPL   189.43 (-0.95%)
MSFT   369.14 (-1.43%)
META   320.02 (-1.48%)
GOOGL   129.27 (-1.96%)
AMZN   144.84 (-1.49%)
TSLA   235.58 (-1.36%)
NVDA   455.10 (-2.68%)
NIO   7.32 (+2.38%)
BABA   73.03 (-1.30%)
AMD   118.57 (-2.32%)
T   16.67 (-0.60%)
F   10.70 (+1.13%)
MU   74.29 (-2.16%)
CGC   0.76 (+22.72%)
GE   121.50 (-0.82%)
DIS   92.01 (-0.62%)
AMC   7.50 (+9.18%)
PFE   29.25 (+1.18%)
PYPL   59.85 (+0.34%)
XOM   102.43 (-0.54%)
Top-Rated StocksTop-RatedPositive News SentimentPositive News

BridgeBio Pharma (BBIO) Stock Forecast & Price Target

$31.94
+1.00 (+3.23%)
(As of 12/4/2023 ET)
Compare
Today's Range
$30.37
▼
$32.42
50-Day Range
$24.02
▼
$30.94
52-Week Range
$6.64
▼
$36.36
Volume
1.73 million shs
Average Volume
2.41 million shs
Market Capitalization
$5.56 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$38.75
Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainability

BridgeBio Pharma Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Moderate Buy
Based on 12 Analyst Ratings

Analysts' Consensus Price Target

$38.75
21.32% Upside
High Forecast$60.00
Average Forecast$38.75
Low Forecast$18.00
TypeCurrent Forecast
12/4/22 to 12/4/23		1 Month Ago
11/4/22 to 11/4/23		3 Months Ago
9/5/22 to 9/5/23		1 Year Ago
12/4/21 to 12/4/22
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
11 Buy rating(s)
10 Buy rating(s)
9 Buy rating(s)
5 Buy rating(s)
Hold
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$38.75$38.45$37.30$23.00
Predicted Upside21.32% Upside59.53% Upside54.84% Upside148.49% Upside
Get BridgeBio Pharma Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for BBIO and its competitors with MarketBeat's FREE daily newsletter.


BBIO Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

BBIO Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

BridgeBio Pharma Stock vs. The Competition

TypeBridgeBio PharmaMedical CompaniesS&P 500
Consensus Rating Score
2.92
2.67
2.49
Consensus RatingModerate BuyModerate BuyHold
Predicted Upside25.24% Upside643.69% Upside13.62% Upside
News Sentiment RatingVery Positive News
Positive News
Positive News

Recent Analyst Ratings and Stock Forecasts

Export to Excel
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
11/7/2023Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Initiated CoverageBuy$42.00+50.65%
10/24/2023Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Initiated CoverageOverweight$50.00+106.27%
8/28/2023Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Reiterated RatingBuy ➝ Buy$60.00+108.55%
8/17/2023JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetOverweight ➝ Overweight$42.00 ➝ $38.00+31.99%
7/18/2023The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetBuy$29.00 ➝ $50.00+56.05%
7/18/2023Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetOutperform$29.00 ➝ $46.00+43.57%
7/18/2023BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost Target$32.00 ➝ $42.00+31.09%
7/17/2023Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 DowngradeBuy ➝ Hold$24.00 ➝ $33.00+3.00%
4/19/2023Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Initiated CoverageOutperform$40.00+164.03%
4/13/2023SVB Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetOutperform$25.00 ➝ $27.00+77.87%
3/7/2023Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost Target$15.00 ➝ $18.00+8.96%
2/6/2023Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Initiated CoverageOutperform
1/23/2023SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetOutperform$23.00 ➝ $19.00+123.00%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 04:54 PM ET.












BBIO Price Target - Frequently Asked Questions

What is BridgeBio Pharma's consensus rating and price target?

According to the issued ratings of 12 analysts in the last year, the consensus rating for BridgeBio Pharma stock is Moderate Buy based on the current 1 hold rating and 11 buy ratings for BBIO. The average twelve-month price prediction for BridgeBio Pharma is $38.75 with a high price target of $60.00 and a low price target of $18.00. Learn more on BBIO's analyst rating history.

Do Wall Street analysts like BridgeBio Pharma more than its competitors?

Analysts like BridgeBio Pharma more than other Medical companies. The consensus rating score for BridgeBio Pharma is 2.92 while the average consensus rating score for medical companies is 2.67. Learn more on how BBIO compares to other companies.

Does BridgeBio Pharma's stock price have much upside?

According to analysts, BridgeBio Pharma's stock has a predicted upside of 58.50% based on their 12-month stock forecasts.

What analysts cover BridgeBio Pharma?

BridgeBio Pharma has been rated by Cantor Fitzgerald, and Citigroup in the past 90 days.


Stock Ratings Reports and Tools

Related Companies:
Today's Ratings:
Top Rated Stocks:
More Ratings Tools:
This page (NASDAQ:BBIO) was last updated on 12/4/2023 by MarketBeat.com Staff

My Account -